Teva Pharmaceutical Industries Ltd (TEVA) Shares Bought by Hexavest Inc.

Hexavest Inc. boosted its stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 2,867.3% during the first quarter, according to its most recent filing with the SEC. The firm owned 321,034 shares of the company’s stock after buying an additional 310,215 shares during the period. Hexavest Inc.’s holdings in Teva Pharmaceutical Industries were worth $10,302,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of TEVA. Paulson & CO. Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at $577,310,000. Norges Bank purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at $495,909,000. Franklin Resources Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 20.9% in the fourth quarter. Franklin Resources Inc. now owns 56,635,303 shares of the company’s stock valued at $2,052,926,000 after buying an additional 9,775,505 shares in the last quarter. Highfields Capital Management LP boosted its stake in shares of Teva Pharmaceutical Industries by 106.2% in the fourth quarter. Highfields Capital Management LP now owns 16,867,447 shares of the company’s stock valued at $611,445,000 after buying an additional 8,686,905 shares in the last quarter. Finally, Barrow Hanley Mewhinney & Strauss LLC boosted its stake in shares of Teva Pharmaceutical Industries by 22.1% in the fourth quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 32,455,432 shares of the company’s stock valued at $1,176,510,000 after buying an additional 5,884,444 shares in the last quarter. 55.03% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) traded up 1.089% during midday trading on Friday, reaching $31.095. 5,087,279 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $32.75 and its 200 day moving average price is $36.56. The firm has a market cap of $31.56 billion, a price-to-earnings ratio of 444.214 and a beta of 0.58. Teva Pharmaceutical Industries Ltd has a 1-year low of $30.57 and a 1-year high of $57.52. Teva Pharmaceutical Industries also was the recipient of unusually large options trading activity on Thursday. Stock traders acquired 422 put options on the stock. This represents an increase of approximately 111% compared to the typical daily volume of 200 put options.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Monday, February 13th. The company reported $1.38 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.36 by $0.02. Teva Pharmaceutical Industries had a net margin of 1.50% and a return on equity of 17.46%. The firm had revenue of $6.25 billion for the quarter, compared to the consensus estimate of $6.26 billion. During the same quarter in the prior year, the company posted $1.32 earnings per share. The business’s revenue was up 33.0% on a year-over-year basis. Equities research analysts anticipate that Teva Pharmaceutical Industries Ltd will post $4.82 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Ltd (TEVA) Shares Bought by Hexavest Inc.” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/2485692/teva-pharmaceutical-industries-ltd-teva-shares-bought-by-hexavest-inc.html.

TEVA has been the topic of a number of research reports. JPMorgan Chase & Co. lowered shares of Teva Pharmaceutical Industries from an “overweight” rating to a “neutral” rating in a research report on Friday, January 20th. Bank of America Corp upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 31st. Vetr lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $37.32 target price on the stock. in a research report on Monday, March 13th. Maxim Group reiterated an “outperform” rating and set a $35.00 target price on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 29th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $42.00 target price on shares of Teva Pharmaceutical Industries in a research report on Friday, February 24th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $45.14.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

5 Day Chart for NYSE:TEVA

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
Shares at Radius Jump as Bone Drug of Amgen Has Setback
Shares at Radius Jump as Bone Drug of Amgen Has Setback
Blackberry Returns as Stock Surges Following WannaCry
Blackberry Returns as Stock Surges Following WannaCry
Flight Attendants Accuse Frontier Airlines of Not Allowing Breast Feeding
Flight Attendants Accuse Frontier Airlines of Not Allowing Breast Feeding
General Motors’ Maven Launches in New York City
General Motors’ Maven Launches in New York City


© 2006-2017 Ticker Report. Google+.